IBDEI02A ; ; 01-AUG-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5256,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Primary
 ;;^UTILITY(U,$J,358.3,5256,1,4,0)
 ;;=4^E27.1
 ;;^UTILITY(U,$J,358.3,5256,2)
 ;;=^5002740
 ;;^UTILITY(U,$J,358.3,5257,0)
 ;;=E27.49^^34^292^13
 ;;^UTILITY(U,$J,358.3,5257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5257,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Other
 ;;^UTILITY(U,$J,358.3,5257,1,4,0)
 ;;=4^E27.49
 ;;^UTILITY(U,$J,358.3,5257,2)
 ;;=^5002743
 ;;^UTILITY(U,$J,358.3,5258,0)
 ;;=E27.3^^34^292^12
 ;;^UTILITY(U,$J,358.3,5258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5258,1,3,0)
 ;;=3^Adrenocortical Insufficiency,Drug-Induced
 ;;^UTILITY(U,$J,358.3,5258,1,4,0)
 ;;=4^E27.3
 ;;^UTILITY(U,$J,358.3,5258,2)
 ;;=^5002741
 ;;^UTILITY(U,$J,358.3,5259,0)
 ;;=E27.5^^34^292^16
 ;;^UTILITY(U,$J,358.3,5259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5259,1,3,0)
 ;;=3^Adrenomedullary Hyperfunction
 ;;^UTILITY(U,$J,358.3,5259,1,4,0)
 ;;=4^E27.5
 ;;^UTILITY(U,$J,358.3,5259,2)
 ;;=^5002744
 ;;^UTILITY(U,$J,358.3,5260,0)
 ;;=N18.1^^34^292^43
 ;;^UTILITY(U,$J,358.3,5260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5260,1,3,0)
 ;;=3^CKD,Stage 1
 ;;^UTILITY(U,$J,358.3,5260,1,4,0)
 ;;=4^N18.1
 ;;^UTILITY(U,$J,358.3,5260,2)
 ;;=^5015602
 ;;^UTILITY(U,$J,358.3,5261,0)
 ;;=N18.2^^34^292^44
 ;;^UTILITY(U,$J,358.3,5261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5261,1,3,0)
 ;;=3^CKD,Stage 2
 ;;^UTILITY(U,$J,358.3,5261,1,4,0)
 ;;=4^N18.2
 ;;^UTILITY(U,$J,358.3,5261,2)
 ;;=^5015603
 ;;^UTILITY(U,$J,358.3,5262,0)
 ;;=N18.31^^34^292^46
 ;;^UTILITY(U,$J,358.3,5262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5262,1,3,0)
 ;;=3^CKD,Stage 3A
 ;;^UTILITY(U,$J,358.3,5262,1,4,0)
 ;;=4^N18.31
 ;;^UTILITY(U,$J,358.3,5262,2)
 ;;=^5159287
 ;;^UTILITY(U,$J,358.3,5263,0)
 ;;=N18.32^^34^292^47
 ;;^UTILITY(U,$J,358.3,5263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5263,1,3,0)
 ;;=3^CKD,Stage 3B
 ;;^UTILITY(U,$J,358.3,5263,1,4,0)
 ;;=4^N18.32
 ;;^UTILITY(U,$J,358.3,5263,2)
 ;;=^5159288
 ;;^UTILITY(U,$J,358.3,5264,0)
 ;;=N18.30^^34^292^45
 ;;^UTILITY(U,$J,358.3,5264,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5264,1,3,0)
 ;;=3^CKD,Stage 3,Unspec
 ;;^UTILITY(U,$J,358.3,5264,1,4,0)
 ;;=4^N18.30
 ;;^UTILITY(U,$J,358.3,5264,2)
 ;;=^5159286
 ;;^UTILITY(U,$J,358.3,5265,0)
 ;;=N18.4^^34^292^48
 ;;^UTILITY(U,$J,358.3,5265,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5265,1,3,0)
 ;;=3^CKD,Stage 4
 ;;^UTILITY(U,$J,358.3,5265,1,4,0)
 ;;=4^N18.4
 ;;^UTILITY(U,$J,358.3,5265,2)
 ;;=^5015605
 ;;^UTILITY(U,$J,358.3,5266,0)
 ;;=N18.5^^34^292^49
 ;;^UTILITY(U,$J,358.3,5266,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5266,1,3,0)
 ;;=3^CKD,Stage 5
 ;;^UTILITY(U,$J,358.3,5266,1,4,0)
 ;;=4^N18.5
 ;;^UTILITY(U,$J,358.3,5266,2)
 ;;=^5015606
 ;;^UTILITY(U,$J,358.3,5267,0)
 ;;=E11.42^^34^292^69
 ;;^UTILITY(U,$J,358.3,5267,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5267,1,3,0)
 ;;=3^Diabetes Type 2 w/ Peripheral Neuropathy
 ;;^UTILITY(U,$J,358.3,5267,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,5267,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,5268,0)
 ;;=E11.43^^34^292^57
 ;;^UTILITY(U,$J,358.3,5268,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5268,1,3,0)
 ;;=3^Diabetes Type 2 w/ Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,5268,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,5268,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,5269,0)
 ;;=E11.52^^34^292^68
 ;;^UTILITY(U,$J,358.3,5269,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5269,1,3,0)
 ;;=3^Diabetes Type 2 w/ Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,5269,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,5269,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,5270,0)
 ;;=Z79.84^^34^292^145
 ;;^UTILITY(U,$J,358.3,5270,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5270,1,3,0)
 ;;=3^Long Term (Current) Use of Oral Hypoglycemics
 ;;^UTILITY(U,$J,358.3,5270,1,4,0)
 ;;=4^Z79.84
 ;;^UTILITY(U,$J,358.3,5270,2)
 ;;=^5140432
 ;;^UTILITY(U,$J,358.3,5271,0)
 ;;=Z79.899^^34^292^146
 ;;^UTILITY(U,$J,358.3,5271,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5271,1,3,0)
 ;;=3^Long Term (Current) Use of Oth Drug Therapy
 ;;^UTILITY(U,$J,358.3,5271,1,4,0)
 ;;=4^Z79.899
 ;;^UTILITY(U,$J,358.3,5271,2)
 ;;=^5063343
 ;;^UTILITY(U,$J,358.3,5272,0)
 ;;=Z79.01^^34^292^140
 ;;^UTILITY(U,$J,358.3,5272,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5272,1,3,0)
 ;;=3^Long Term (Current) Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,5272,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,5272,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,5273,0)
 ;;=Z79.02^^34^292^141
 ;;^UTILITY(U,$J,358.3,5273,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5273,1,3,0)
 ;;=3^Long Term (Current) Use of Antithrombotics/Antiplatelets
 ;;^UTILITY(U,$J,358.3,5273,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,5273,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,5274,0)
 ;;=Z79.82^^34^292^142
 ;;^UTILITY(U,$J,358.3,5274,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5274,1,3,0)
 ;;=3^Long Term (Current) Use of Aspirin
 ;;^UTILITY(U,$J,358.3,5274,1,4,0)
 ;;=4^Z79.82
 ;;^UTILITY(U,$J,358.3,5274,2)
 ;;=^5063340
 ;;^UTILITY(U,$J,358.3,5275,0)
 ;;=Z79.51^^34^292^143
 ;;^UTILITY(U,$J,358.3,5275,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5275,1,3,0)
 ;;=3^Long Term (Current) Use of Inhaled Steroids
 ;;^UTILITY(U,$J,358.3,5275,1,4,0)
 ;;=4^Z79.51
 ;;^UTILITY(U,$J,358.3,5275,2)
 ;;=^5063335
 ;;^UTILITY(U,$J,358.3,5276,0)
 ;;=Z79.52^^34^292^147
 ;;^UTILITY(U,$J,358.3,5276,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5276,1,3,0)
 ;;=3^Long Term (Current) Use of Systemic Steroids
 ;;^UTILITY(U,$J,358.3,5276,1,4,0)
 ;;=4^Z79.52
 ;;^UTILITY(U,$J,358.3,5276,2)
 ;;=^5063336
 ;;^UTILITY(U,$J,358.3,5277,0)
 ;;=E22.8^^34^292^200
 ;;^UTILITY(U,$J,358.3,5277,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5277,1,3,0)
 ;;=3^Pituitary Hyperfunction,Other
 ;;^UTILITY(U,$J,358.3,5277,1,4,0)
 ;;=4^E22.8
 ;;^UTILITY(U,$J,358.3,5277,2)
 ;;=^5002719
 ;;^UTILITY(U,$J,358.3,5278,0)
 ;;=E22.2^^34^292^221
 ;;^UTILITY(U,$J,358.3,5278,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5278,1,3,0)
 ;;=3^SIADH
 ;;^UTILITY(U,$J,358.3,5278,1,4,0)
 ;;=4^E22.2
 ;;^UTILITY(U,$J,358.3,5278,2)
 ;;=^5002718
 ;;^UTILITY(U,$J,358.3,5279,0)
 ;;=T45.1X5A^^34^292^20
 ;;^UTILITY(U,$J,358.3,5279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5279,1,3,0)
 ;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Init Enctr
 ;;^UTILITY(U,$J,358.3,5279,1,4,0)
 ;;=4^T45.1X5A
 ;;^UTILITY(U,$J,358.3,5279,2)
 ;;=^5051026
 ;;^UTILITY(U,$J,358.3,5280,0)
 ;;=T45.1X5D^^34^292^21
 ;;^UTILITY(U,$J,358.3,5280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5280,1,3,0)
 ;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Subsq
 ;;^UTILITY(U,$J,358.3,5280,1,4,0)
 ;;=4^T45.1X5D
 ;;^UTILITY(U,$J,358.3,5280,2)
 ;;=^5051027
 ;;^UTILITY(U,$J,358.3,5281,0)
 ;;=T45.1X5S^^34^292^22
 ;;^UTILITY(U,$J,358.3,5281,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5281,1,3,0)
 ;;=3^Adverse Effect,Antineoplastic/Immunosuppressive,Sequela
 ;;^UTILITY(U,$J,358.3,5281,1,4,0)
 ;;=4^T45.1X5S
 ;;^UTILITY(U,$J,358.3,5281,2)
 ;;=^5051028
 ;;^UTILITY(U,$J,358.3,5282,0)
 ;;=T46.2X5A^^34^292^17
 ;;^UTILITY(U,$J,358.3,5282,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5282,1,3,0)
 ;;=3^Adverse Effect,Antidysrhthmic,Init Encntr
 ;;^UTILITY(U,$J,358.3,5282,1,4,0)
 ;;=4^T46.2X5A
 ;;^UTILITY(U,$J,358.3,5282,2)
 ;;=^5051296
 ;;^UTILITY(U,$J,358.3,5283,0)
 ;;=T46.2X5D^^34^292^19
 ;;^UTILITY(U,$J,358.3,5283,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5283,1,3,0)
 ;;=3^Adverse Effect,Antidysrhthmic,Subsq
 ;;^UTILITY(U,$J,358.3,5283,1,4,0)
 ;;=4^T46.2X5D
 ;;^UTILITY(U,$J,358.3,5283,2)
 ;;=^5051297
 ;;^UTILITY(U,$J,358.3,5284,0)
 ;;=T46.2X5S^^34^292^18
 ;;^UTILITY(U,$J,358.3,5284,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5284,1,3,0)
 ;;=3^Adverse Effect,Antidysrhthmic,Sequela
 ;;^UTILITY(U,$J,358.3,5284,1,4,0)
 ;;=4^T46.2X5S
 ;;^UTILITY(U,$J,358.3,5284,2)
 ;;=^5051298
 ;;^UTILITY(U,$J,358.3,5285,0)
 ;;=N91.0^^34^292^24
 ;;^UTILITY(U,$J,358.3,5285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5285,1,3,0)
 ;;=3^Amenorrhea,Primary
 ;;^UTILITY(U,$J,358.3,5285,1,4,0)
 ;;=4^N91.0
 ;;^UTILITY(U,$J,358.3,5285,2)
 ;;=^5015902
 ;;^UTILITY(U,$J,358.3,5286,0)
 ;;=N91.1^^34^292^25
 ;;^UTILITY(U,$J,358.3,5286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5286,1,3,0)
 ;;=3^Amenorrhea,Secondary
 ;;^UTILITY(U,$J,358.3,5286,1,4,0)
 ;;=4^N91.1
 ;;^UTILITY(U,$J,358.3,5286,2)
 ;;=^5015903
 ;;^UTILITY(U,$J,358.3,5287,0)
 ;;=N91.2^^34^292^26
 ;;^UTILITY(U,$J,358.3,5287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5287,1,3,0)
 ;;=3^Amenorrhea,Unspec
 ;;^UTILITY(U,$J,358.3,5287,1,4,0)
 ;;=4^N91.2
 ;;^UTILITY(U,$J,358.3,5287,2)
 ;;=^5015904
 ;;^UTILITY(U,$J,358.3,5288,0)
 ;;=Z98.84^^34^292^33
 ;;^UTILITY(U,$J,358.3,5288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5288,1,3,0)
 ;;=3^Bariatric Surgery Status
 ;;^UTILITY(U,$J,358.3,5288,1,4,0)
 ;;=4^Z98.84
 ;;^UTILITY(U,$J,358.3,5288,2)
 ;;=^5063749
 ;;^UTILITY(U,$J,358.3,5289,0)
 ;;=N18.6^^34^292^50
 ;;^UTILITY(U,$J,358.3,5289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5289,1,3,0)
 ;;=3^CKD,Stage 6 (ESRD)
 ;;^UTILITY(U,$J,358.3,5289,1,4,0)
 ;;=4^N18.6
 ;;^UTILITY(U,$J,358.3,5289,2)
 ;;=^303986
 ;;^UTILITY(U,$J,358.3,5290,0)
 ;;=E25.0^^34^292^11
 ;;^UTILITY(U,$J,358.3,5290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5290,1,3,0)
 ;;=3^Adrenal Hyperplasia,Congenital
 ;;^UTILITY(U,$J,358.3,5290,1,4,0)
 ;;=4^E25.0
 ;;^UTILITY(U,$J,358.3,5290,2)
 ;;=^5002732
 ;;^UTILITY(U,$J,358.3,5291,0)
 ;;=E11.69^^34^292^67
 ;;^UTILITY(U,$J,358.3,5291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5291,1,3,0)
 ;;=3^Diabetes Type 2 w/ Oth Specified Complication
 ;;^UTILITY(U,$J,358.3,5291,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,5291,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,5292,0)
 ;;=F64.0^^34^292^76
 ;;^UTILITY(U,$J,358.3,5292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5292,1,3,0)
 ;;=3^Gender Dysphoria
 ;;^UTILITY(U,$J,358.3,5292,1,4,0)
 ;;=4^F64.0
 ;;^UTILITY(U,$J,358.3,5292,2)
 ;;=^121404
 ;;^UTILITY(U,$J,358.3,5293,0)
 ;;=E05.01^^34^292^78
 ;;^UTILITY(U,$J,358.3,5293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5293,1,3,0)
 ;;=3^Graves Disease w/ Thyrotoxic Crisis/Storm
 ;;^UTILITY(U,$J,358.3,5293,1,4,0)
 ;;=4^E05.01
 ;;^UTILITY(U,$J,358.3,5293,2)
 ;;=^5002482
 ;;^UTILITY(U,$J,358.3,5294,0)
 ;;=E28.1^^34^292^100
 ;;^UTILITY(U,$J,358.3,5294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5294,1,3,0)
 ;;=3^Hyperandrogenism
 ;;^UTILITY(U,$J,358.3,5294,1,4,0)
 ;;=4^E28.1
 ;;^UTILITY(U,$J,358.3,5294,2)
 ;;=^5002748
 ;;^UTILITY(U,$J,358.3,5295,0)
 ;;=E87.5^^34^292^103
 ;;^UTILITY(U,$J,358.3,5295,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5295,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,5295,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,5295,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,5296,0)
 ;;=I50.1^^34^292^90
 ;;^UTILITY(U,$J,358.3,5296,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5296,1,3,0)
 ;;=3^Heart Failure,Left Ventricular
 ;;^UTILITY(U,$J,358.3,5296,1,4,0)
 ;;=4^I50.1
 ;;^UTILITY(U,$J,358.3,5296,2)
 ;;=^5007238
 ;;^UTILITY(U,$J,358.3,5297,0)
 ;;=I50.21^^34^292^95
 ;;^UTILITY(U,$J,358.3,5297,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5297,1,3,0)
 ;;=3^Heart Failure,Systolic,Acute
 ;;^UTILITY(U,$J,358.3,5297,1,4,0)
 ;;=4^I50.21
 ;;^UTILITY(U,$J,358.3,5297,2)
 ;;=^5007240
 ;;^UTILITY(U,$J,358.3,5298,0)
 ;;=I50.22^^34^292^97
 ;;^UTILITY(U,$J,358.3,5298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5298,1,3,0)
 ;;=3^Heart Failure,Systolic,Chronic
 ;;^UTILITY(U,$J,358.3,5298,1,4,0)
 ;;=4^I50.22
 ;;^UTILITY(U,$J,358.3,5298,2)
 ;;=^5007241
 ;;^UTILITY(U,$J,358.3,5299,0)
 ;;=I50.23^^34^292^96
 ;;^UTILITY(U,$J,358.3,5299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5299,1,3,0)
 ;;=3^Heart Failure,Systolic,Acute on Chronic
 ;;^UTILITY(U,$J,358.3,5299,1,4,0)
 ;;=4^I50.23
 ;;^UTILITY(U,$J,358.3,5299,2)
 ;;=^5007242
 ;;^UTILITY(U,$J,358.3,5300,0)
 ;;=I50.31^^34^292^85
 ;;^UTILITY(U,$J,358.3,5300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5300,1,3,0)
 ;;=3^Heart Failure,Diastolic,Acute
 ;;^UTILITY(U,$J,358.3,5300,1,4,0)
 ;;=4^I50.31
 ;;^UTILITY(U,$J,358.3,5300,2)
 ;;=^5007244
 ;;^UTILITY(U,$J,358.3,5301,0)
 ;;=I50.32^^34^292^87
 ;;^UTILITY(U,$J,358.3,5301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5301,1,3,0)
 ;;=3^Heart Failure,Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,5301,1,4,0)
 ;;=4^I50.32
 ;;^UTILITY(U,$J,358.3,5301,2)
 ;;=^5007245
 ;;^UTILITY(U,$J,358.3,5302,0)
 ;;=I50.33^^34^292^86
 ;;^UTILITY(U,$J,358.3,5302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5302,1,3,0)
 ;;=3^Heart Failure,Diastolic,Acute on Chronic
 ;;^UTILITY(U,$J,358.3,5302,1,4,0)
 ;;=4^I50.33
 ;;^UTILITY(U,$J,358.3,5302,2)
 ;;=^5007246
 ;;^UTILITY(U,$J,358.3,5303,0)
 ;;=I50.41^^34^292^82
 ;;^UTILITY(U,$J,358.3,5303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5303,1,3,0)
 ;;=3^Heart Failure,Combined,Acute
 ;;^UTILITY(U,$J,358.3,5303,1,4,0)
 ;;=4^I50.41
 ;;^UTILITY(U,$J,358.3,5303,2)
 ;;=^5007248
 ;;^UTILITY(U,$J,358.3,5304,0)
 ;;=I50.42^^34^292^84
 ;;^UTILITY(U,$J,358.3,5304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5304,1,3,0)
 ;;=3^Heart Failure,Combined,Chronic
 ;;^UTILITY(U,$J,358.3,5304,1,4,0)
 ;;=4^I50.42
 ;;^UTILITY(U,$J,358.3,5304,2)
 ;;=^5007249
 ;;^UTILITY(U,$J,358.3,5305,0)
 ;;=I50.43^^34^292^83
 ;;^UTILITY(U,$J,358.3,5305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5305,1,3,0)
 ;;=3^Heart Failure,Combined,Acute on Chronic
 ;;^UTILITY(U,$J,358.3,5305,1,4,0)
 ;;=4^I50.43
 ;;^UTILITY(U,$J,358.3,5305,2)
 ;;=^5007250
 ;;^UTILITY(U,$J,358.3,5306,0)
 ;;=I50.811^^34^292^92
 ;;^UTILITY(U,$J,358.3,5306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5306,1,3,0)
 ;;=3^Heart Failure,Right,Acute
 ;;^UTILITY(U,$J,358.3,5306,1,4,0)
 ;;=4^I50.811
 ;;^UTILITY(U,$J,358.3,5306,2)
 ;;=^5151385
 ;;^UTILITY(U,$J,358.3,5307,0)
 ;;=I50.812^^34^292^94
 ;;^UTILITY(U,$J,358.3,5307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5307,1,3,0)
 ;;=3^Heart Failure,Right,Chronic
 ;;^UTILITY(U,$J,358.3,5307,1,4,0)
 ;;=4^I50.812
 ;;^UTILITY(U,$J,358.3,5307,2)
 ;;=^5151386
 ;;^UTILITY(U,$J,358.3,5308,0)
 ;;=I50.813^^34^292^93
 ;;^UTILITY(U,$J,358.3,5308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5308,1,3,0)
 ;;=3^Heart Failure,Right,Acute on Chronic
 ;;^UTILITY(U,$J,358.3,5308,1,4,0)
 ;;=4^I50.813
 ;;^UTILITY(U,$J,358.3,5308,2)
 ;;=^5151387
 ;;^UTILITY(U,$J,358.3,5309,0)
 ;;=I50.814^^34^292^91
 ;;^UTILITY(U,$J,358.3,5309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5309,1,3,0)
 ;;=3^Heart Failure,Right due to Left
 ;;^UTILITY(U,$J,358.3,5309,1,4,0)
 ;;=4^I50.814
 ;;^UTILITY(U,$J,358.3,5309,2)
 ;;=^5151388
 ;;^UTILITY(U,$J,358.3,5310,0)
 ;;=I50.82^^34^292^81
 ;;^UTILITY(U,$J,358.3,5310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5310,1,3,0)
 ;;=3^Heart Failure,Biventricular
 ;;^UTILITY(U,$J,358.3,5310,1,4,0)
 ;;=4^I50.82
 ;;^UTILITY(U,$J,358.3,5310,2)
 ;;=^5151389
 ;;^UTILITY(U,$J,358.3,5311,0)
 ;;=I50.83^^34^292^89
 ;;^UTILITY(U,$J,358.3,5311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5311,1,3,0)
 ;;=3^Heart Failure,High Output
 ;;^UTILITY(U,$J,358.3,5311,1,4,0)
 ;;=4^I50.83
 ;;^UTILITY(U,$J,358.3,5311,2)
 ;;=^5151390
 ;;^UTILITY(U,$J,358.3,5312,0)
 ;;=I50.84^^34^292^88
 ;;^UTILITY(U,$J,358.3,5312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5312,1,3,0)
 ;;=3^Heart Failure,End Stage
 ;;^UTILITY(U,$J,358.3,5312,1,4,0)
 ;;=4^I50.84
 ;;^UTILITY(U,$J,358.3,5312,2)
 ;;=^5151391
 ;;^UTILITY(U,$J,358.3,5313,0)
 ;;=L68.0^^34^292^98
 ;;^UTILITY(U,$J,358.3,5313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5313,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,5313,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,5313,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,5314,0)
 ;;=I11.0^^34^292^117
 ;;^UTILITY(U,$J,358.3,5314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5314,1,3,0)
 ;;=3^Hypertensive Hrt Disease w/ Hrt Failure
 ;;^UTILITY(U,$J,358.3,5314,1,4,0)
 ;;=4^I11.0
 ;;^UTILITY(U,$J,358.3,5314,2)
 ;;=^5007063
 ;;^UTILITY(U,$J,358.3,5315,0)
 ;;=I11.9^^34^292^118
 ;;^UTILITY(U,$J,358.3,5315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5315,1,3,0)
 ;;=3^Hypertensive Hrt Disease w/o Hrt Failure
 ;;^UTILITY(U,$J,358.3,5315,1,4,0)
 ;;=4^I11.9
 ;;^UTILITY(U,$J,358.3,5315,2)
 ;;=^5007064
 ;;^UTILITY(U,$J,358.3,5316,0)
 ;;=I12.0^^34^292^120
 ;;^UTILITY(U,$J,358.3,5316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5316,1,3,0)
 ;;=3^Hypertensive Kidney Disease w/ CKD5/ESRD
 ;;^UTILITY(U,$J,358.3,5316,1,4,0)
 ;;=4^I12.0
 ;;^UTILITY(U,$J,358.3,5316,2)
 ;;=^5007065
 ;;^UTILITY(U,$J,358.3,5317,0)
 ;;=I12.9^^34^292^119
 ;;^UTILITY(U,$J,358.3,5317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5317,1,3,0)
 ;;=3^Hypertensive Kidney Disease w/ CKD1-CKD4
 ;;^UTILITY(U,$J,358.3,5317,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,5317,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,5318,0)
 ;;=I13.0^^34^292^113
 ;;^UTILITY(U,$J,358.3,5318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5318,1,3,0)
 ;;=3^Hypertensive Hrt & Kidney Disease w/ CKD1-CKD4
 ;;^UTILITY(U,$J,358.3,5318,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,5318,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,5319,0)
 ;;=I13.10^^34^292^115
 ;;^UTILITY(U,$J,358.3,5319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5319,1,3,0)
 ;;=3^Hypertensive Hrt Diseas w/o CHF w/ CKD1-CKD4
 ;;^UTILITY(U,$J,358.3,5319,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,5319,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,5320,0)
 ;;=I13.11^^34^292^116
 ;;^UTILITY(U,$J,358.3,5320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5320,1,3,0)
 ;;=3^Hypertensive Hrt Diseas w/o CHF w/ CKD5/ESRD
 ;;^UTILITY(U,$J,358.3,5320,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,5320,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,5321,0)
 ;;=I13.2^^34^292^114
 ;;^UTILITY(U,$J,358.3,5321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5321,1,3,0)
 ;;=3^Hypertensive Hrt & Kidney Disease w/ CKD5/ESRD
 ;;^UTILITY(U,$J,358.3,5321,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,5321,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,5322,0)
 ;;=E87.6^^34^292^126
 ;;^UTILITY(U,$J,358.3,5322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5322,1,3,0)
 ;;=3^Hypokalemia
 ;;^UTILITY(U,$J,358.3,5322,1,4,0)
 ;;=4^E87.6
 ;;^UTILITY(U,$J,358.3,5322,2)
 ;;=^60610
 ;;^UTILITY(U,$J,358.3,5323,0)
 ;;=E87.1^^34^292^127
 ;;^UTILITY(U,$J,358.3,5323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5323,1,3,0)
 ;;=3^Hyponatremia
 ;;^UTILITY(U,$J,358.3,5323,1,4,0)
 ;;=4^E87.1
 ;;^UTILITY(U,$J,358.3,5323,2)
 ;;=^5003019
 ;;^UTILITY(U,$J,358.3,5324,0)
 ;;=E23.6^^34^292^128
 ;;^UTILITY(U,$J,358.3,5324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5324,1,3,0)
 ;;=3^Hypophysitis
 ;;^UTILITY(U,$J,358.3,5324,1,4,0)
 ;;=4^E23.6
 ;;^UTILITY(U,$J,358.3,5324,2)
 ;;=^5002723
 ;;^UTILITY(U,$J,358.3,5325,0)
 ;;=Q98.0^^34^292^136
 ;;^UTILITY(U,$J,358.3,5325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5325,1,3,0)
 ;;=3^Klinefelter Syndrome,Karyotype 47,XXY
 ;;^UTILITY(U,$J,358.3,5325,1,4,0)
 ;;=4^Q98.0
 ;;^UTILITY(U,$J,358.3,5325,2)
 ;;=^5019149
 ;;^UTILITY(U,$J,358.3,5326,0)
 ;;=Q98.1^^34^292^137
